Speech-Language Pathologists in Tucumcari, NM Accepting Medicare
6 Speech-Language Pathologists found. Showing 1 - 6
 Billie Denise Lindsey, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1107 South Eleventh Street, Tucumcari, NM 88401 Phone: 505-461-4344 Fax: 505-461-8033 |
Becky Whitson Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1107 South Eleventh Street, Tucumcari, NM 88401 Phone: 505-461-4344 |
Chanda Reisha Baker, M.S., CFY-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1701 South 11th St., Tucumcari, NM 88401 Phone: 575-461-4344 Fax: 575-461-8033 |
Ms. Penny J Huerta, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2400 S 8th St, Tucumcari, NM 88401 Phone: 505-461-4344 |
Ashley Renee Mcclelland Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 301 E Miel De Luna Ave, Tucumcari, NM 88401 Phone: 575-461-7000 |
Hannah Brooke Walker, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1701 S 11th St, Tucumcari, NM 88401 Phone: 575-461-4344 Fax: 575-461-8033 |
News Archive
New therapeutic approach for women with estrogen-receptor-positive breast cancer
Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.
ACS, Alliance begin work on second volume of manual for cancer surgery
The American College of Surgeons and the Alliance for Clinical Trials in Oncology announced that they have begun work on the second volume of a comprehensive, evidence-based examination of cancer surgery techniques and recommendations.
FDA approves Banzel (rufinamide) for Lennox-Gastaut syndrome
The U.S. Food and Drug Administration has approved a new drug, Banzel (rufinamide), for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome.
Rexahn obtains additional patent coverage for anti-cancer candidate RX-1792 in Japan
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled "Quinazoline Derivatives and Therapeutic Use Thereof."
› Verified 5 days ago
Speech-Language Pathologists
Physical Therapists
Optometrists
Chiropractors
Occupational Therapists